Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Autism Disorder and Treatment Market

ID: MRFR/Pharma/14713-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

์žํ์ฆ ์žฅ์•  ๋ฐ ์น˜๋ฃŒ ์‹œ์žฅ ์กฐ์‚ฌ ๋ณด๊ณ ์„œ โ€“ 2032๋…„ ์˜ˆ์ธก

๊ณต์œ 
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 ๋ณด๊ณ ์„œ ํ”„๋กค๋กœ๊ทธ
  2. 2 ์‹œ์žฅ ์†Œ๊ฐœ
    1. 2.1 ์—ฐ๊ตฌ ๋ฒ”์œ„ 17
    2. 2.2 ์—ฐ๊ตฌ ๋ชฉํ‘œ 17
    3. 2.3 ๊ฐ€์ • ๋ฐ amp; ์ œํ•œ ์‚ฌํ•ญ 17
      1. 2.3.1 ๊ฐ€์ • 17
      2. 2.3.2 ์ œํ•œ ์‚ฌํ•ญ 17
  3. 3 ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก 
    1. 3.1 1์ฐจ ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก  19
    2. 3.2 2์ฐจ ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก  20
    3. 3.3 ์‹œ์žฅ ์ ์œ ์œจ ๋ถ„์„ 21
    4. 3.4 ๋ฌด์—ญ ๋ถ„์„ 21
    5. 3.5 ์‹œ์žฅ ๊ฐ€๊ฒฉ ์ ‘๊ทผ ๋ฐฉ์‹ 21
  4. 4 ์‹œ์žฅ ์—ญํ•™
    1. 4.1 ์„œ๋ก  23
    2. 4.2 ๋™์ธ 24
      1. 4.2.1 ์žํ์ฆ ์žฅ์•  ๋ฐ ์ „๋ฐ˜์  ๋ฐœ๋‹ฌ ์žฅ์• ์˜ ํ™•์‚ฐ์ด ์‹œ์žฅ ์„ฑ์žฅ์„ ์ด‰์ง„ํ–ˆ์Šต๋‹ˆ๋‹ค.(PDD) 24
      2. 4.2.2 ์žํ์ฆ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ๋ผ๋ฒจ ์™ธ ์•ฝ๋ฌผ์˜ ์˜ˆ์ƒ ์Šน์ธ์ด ์‹œ์žฅ ์„ฑ์žฅ์„ ์ฃผ๋„ํ–ˆ์Šต๋‹ˆ๋‹ค. 25
      3. 4.2.3 ์ •๋ถ€ ๋˜๋Š” ๋ฏผ๊ฐ„ ๊ธฐ์—…์˜ ๋ถ€์ƒ ์งˆ๋ณ‘์— ๋Œ€ํ•œ ์ธ์‹์„ ์ œ๊ณ ํ•˜๊ธฐ ์œ„ํ•ด ์•ž์žฅ์„œ๊ณ  ์žˆ๋Š” ์‚ฌํšŒ 26
    3. 4.3 ์ œํ•œ ์‚ฌํ•ญ 27
      1. 4.3.1 ์žํ์ฆ์„ ์œ„ํ•œ ์ฒซ ๋ฒˆ์งธ ์•ฝ๋ฌผ์˜ ์•ฝํ•œ ์ œํ’ˆ ํŒŒ์ดํ”„๋ผ์ธ 27
      2. 4.3.2 ์งˆ๋ณ‘์˜ ์•Œ๋ ค์ง€์ง€ ์•Š์€ ๋ณ‘์ธ ๋ฐ ๋ณ‘ํƒœ์ƒ๋ฆฌํ•™์œผ๋กœ ์ธํ•ด ํšจ๊ณผ์ ์ธ ์น˜๋ฃŒ ์˜ต์…˜ ๋ฐฉ์ง€ 28
    4. 4.4 ๊ธฐํšŒ 29
      1. 4.4.1 ๋ฒค์ฒ˜ ๋น„์•ฝ๋ฆฌํ•™์˜ ํˆฌ์ž ์ฆ๊ฐ€ ํ™œ๋™ 29
    5. 4.5 ๋ฉ”๊ฐ€ ํŠธ๋ Œ๋“œ 30
    6. 4.6 ๊ฑฐ์‹œ ๊ฒฝ์ œ ์ง€ํ‘œ
  5. 5 ์‹œ์žฅ ์š”์ธ ๋ถ„์„
    1. 5.1 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ชจ๋ธ 32
      1. 5.1.1 ๊ณต๊ธ‰์—…์ฒด์˜ ํ˜‘์ƒ๋ ฅ 33
      2. 5.1.2 ๊ตฌ๋งค์ž์˜ ํ˜‘์ƒ๋ ฅ 33
      3. 5.1.3 ์‹ ๊ทœ ์ง„์ž…์ž์˜ ์œ„ํ˜‘ 33
      4. 5.1.4 ์œ„ํ˜‘ ๋Œ€์ฒดํ’ˆ ์ˆ˜ 33
      5. 5.1.5 ๊ฒฝ์Ÿ ๊ฐ•๋„ 33
    2. 5.2 ๊ฐ€์น˜ ์‚ฌ์Šฌ ๋ถ„์„ 34
      1. 5.2.1 R&D 34
      2. 5.2.2 ์ œ์กฐ 34
      3. 5.2.3 ์œ ํ†ต & ํŒ๋งค 34
      4. 5.2.4 ํŒ๋งค ํ›„ ๋ชจ๋‹ˆํ„ฐ๋ง 35
    3. 5.3 ๊ฐ€๊ฒฉ ๋ถ„์„ 36
    4. 5.4 ํˆฌ์ž ๊ธฐํšŒ ๋ถ„์„ 36
    5. 5.5 ์ˆ˜์š” ๋ฐ amp; ๊ณต๊ธ‰: ๊ฒฉ์ฐจ ๋ถ„์„ 36
  6. 6 ์žํ์ฆ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    1. 6.1 ์„œ๋‘ 39
    2. 6.2 ์•„์Šคํผ๊ฑฐ ์ฆํ›„๊ตฐ 40
    3. 6.3 ์ „๋ฐ˜์  ๋ฐœ๋‹ฌ ์žฅ์• (PDD) 40
  7. 7 ์žํ ์žฅ์•  & ์น˜๋ฃŒ ์‹œ์žฅ, ์น˜๋ฃŒ ์œ ํ˜•๋ณ„
    1. 7.1 ์„œ๋ก  42
    2. 7.2 ์ „๋ฌธ๊ฐ€ ์˜๊ฒฌ: ์˜ฅ์‹œํ† ์‹  42
    3. 7.3 ABA(์‘์šฉ ํ–‰๋™ ๋ถ„์„) 43
    4. 7.4 ๊ณ ์•• ์‚ฐ์†Œ ์š”๋ฒ• 44
    5. 7.5 ํ‚ฌ๋ ˆ์ด์…˜ ์š”๋ฒ• 44
    6. 7.6 ์˜ฅ์‹œํ† ์‹  ์š”๋ฒ• 44
  8. 8 ์žํ์ฆ ์žฅ์•  ๋ฐ amp; ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    1. 8.1 ์„œ๋ก  46
    2. 8.2 ์„ ํƒ์  ์„ธ๋กœํ† ๋‹Œ ์žฌํก์ˆ˜ ์–ต์ œ์ œ(SSRI) 47
    3. 8.3 ํ•ญ๊ฒฝ๋ จ์ œ 48
    4. 8.4 ์ž๊ทน์ œ 48
    5. 8.5 ํ•ญ์ •์‹ ๋ณ‘ 48
  9. 9 ๊ธ€๋กœ๋ฒŒ ์žํ ์žฅ์•  & ์ง€์—ญ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    1. 9.1 ์†Œ๊ฐœ 50
    2. 9.2 ๋ฏธ์ฃผ 51
    3. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    4. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    5. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    6. 9.3 ๋ถ๋ฏธ 54
      1. 9.3.1 ๋ฏธ๊ตญ 54๊ฐœ
    7. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    8. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    9. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    10. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    11. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    12. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    13. 9.4 ์บ๋‚˜๋‹ค 55
      1. 9.4.1 ๋‚จ์•„๋ฉ”๋ฆฌ์นด 56
    14. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    15. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    16. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    17. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    18. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    19. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    20. 9.5 ์œ ๋Ÿฝ 57
      1. 9.5.1 ๋…์ผ 60
      2. 9.5.2 ํ”„๋ž‘์Šค 61
      3. 9.5.3 ์˜๊ตญ 62
      4. 9.5.4 ์ดํƒˆ๋ฆฌ์•„ 63
      5. 9.5.5 ์ŠคํŽ˜์ธ 64
      6. 9.5.6 ์„œ์œ ๋Ÿฝ ๋‚˜๋จธ์ง€ ์ง€์—ญ 65
      7. 9.5.7 ๋™์œ ๋Ÿฝ 66
    21. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    22. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    23. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    24. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    25. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    26. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    27. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    28. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    29. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    30. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    31. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    32. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    33. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    34. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    35. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    36. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    37. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    38. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    39. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    40. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    41. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    42. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    43. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    44. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    45. 9.6 ์•„์‹œ์•„ ํƒœํ‰์–‘ 67
      1. 9.6.1 ์ผ๋ณธ 69
      2. 9.6.2 ์ค‘๊ตญ 70
      3. 9.6.3 ์ธ๋„ 71
      4. 9.6.4 ํ˜ธ์ฃผ 72
      5. 9.6.5 ๋Œ€ํ•œ๋ฏผ๊ตญ 73
      6. 9.6.6 ๊ธฐํƒ€ ์•„์‹œ์•„ ํƒœํ‰์–‘ ์ง€์—ญ 74
    46. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    47. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    48. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    49. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    50. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    51. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    52. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    53. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    54. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    55. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    56. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    57. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    58. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    59. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    60. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    61. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    62. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    63. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    64. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    65. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    66. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    67. 9.7 ์ค‘๋™ ๋ฐ amp; ์•„ํ”„๋ฆฌ์นด 76
      1. 9.7.1 U.A.E. 78
      2. 9.7.2 ์‚ฌ์šฐ๋””์•„๋ผ๋น„์•„ 79
      3. 9.7.3 ์˜ค๋งŒ 80
      4. 9.7.4 ์ฟ ์›จ์ดํŠธ 81
      5. 9.7.5 ์นดํƒ€๋ฅด 82
      6. 9.7.6 ์ค‘๋™ ๋ฐ ๊ธฐํƒ€ ์ง€์—ญ ์•„ํ”„๋ฆฌ์นด 83
    68. ์žํ ์žฅ์•  ๋ฐamp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    69. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    70. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    71. ์žํ ์žฅ์•  ๋ฐamp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    72. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    73. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    74. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    75. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    76. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    77. ์žํ ์žฅ์•  ๋ฐ amp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    78. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    79. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    80. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    81. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    82. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    83. ์žํ ์žฅ์•  & ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    84. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    85. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    86. ์žํ ์žฅ์•  ๋ฐamp; ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    87. ์žํ ์žฅ์•  ๋ฐamp; ์น˜๋ฃŒ ์œ ํ˜•๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
    88. ์žํ ์žฅ์•  & ์•ฝ๋ฌผ๋ณ„ ์น˜๋ฃŒ ์‹œ์žฅ
  10. 10 ๊ฒฝ์Ÿ ํ™˜๊ฒฝ
    1. 10.1 ํšŒ์‚ฌ ์‹œ์žฅ ์ ์œ ์œจ ๋ถ„์„ 86
      1. 10.1.1 ์„œ๋ฌธ 86
    2. 10.2 ๊ฒฝ์Ÿ ํ™˜๊ฒฝ 87
      1. 10.2.1 ์„œ๋ฌธ 87
    3. 10.3 ์ตœ๊ทผ ๊ฐœ๋ฐœ, 2013~2018 88
  11. 11 ํšŒ์‚ฌ ํ”„๋กœํ•„
    1. 11.1 Pfizer Inc. 91
      1. 11.1.1 ํšŒ์‚ฌ ๊ฐœ์š” 91
      2. 11.1.2 ์žฌ๋ฌด 91
      3. 11.1.3 ์ œํ’ˆ 91
      4. 11.1.4 ์ „๋žต 91
      5. 11.1.5 ์ฃผ์š” ๊ฐœ๋ฐœ 91
    2. 11.2 Allergan, Plc 92
      1. 11.2.1 ํšŒ์‚ฌ ๊ฐœ์š” 92
      2. 11.2.2 ์žฌ๋ฌด 92
      3. 11.2.3 ์ œํ’ˆ 92
      4. 11.2.4 ์ „๋žต 92
      5. 11.2.5 ์ฃผ์š” ๊ฐœ๋ฐœ 92
    3. 11.3 Eli Lilly ๋ฐ ํšŒ์‚ฌ 93
      1. 11.3.1 ํšŒ์‚ฌ ๊ฐœ์š” 93
      2. 11.3.2 ์žฌ๋ฌด 93
      3. 11.3.3 ์ œํ’ˆ 93
      4. 11.3.4 ์ „๋žต 93
      5. 11.3.5 ์ฃผ์š” ๊ฐœ๋ฐœ 93
    4. 11.4 Bristol-Myers Squibb ํšŒ์‚ฌ 94
      1. 11.4.1 ํšŒ์‚ฌ ๊ฐœ์š” 94
      2. 11.4.2 ์žฌ๋ฌด 94
      3. 11.4.3 ์ œํ’ˆ 94
      4. 11.4.4 ์ „๋žต 94
      5. 11.4.5 ์ฃผ์š” ๊ฐœ๋ฐœ 94
    5. 11.5 Sun Pharmaceutical Industries Ltd. 95
      1. 11.5.1 ํšŒ์‚ฌ ๊ฐœ์š” 95
      2. 11.5.2 ์žฌ๋ฌด 95
      3. 11.5.3 ์ œํ’ˆ 95
      4. 11.5.4 ์ „๋žต 95
      5. 11.5.5 ์ฃผ์š” ๊ฐœ๋ฐœ 95
    6. 11.6 Johnson & Johnson Services, Inc. 96
      1. 11.6.1 ํšŒ์‚ฌ ๊ฐœ์š” 96
      2. 11.6.2 ์žฌ๋ฌด 96
      3. 11.6.3 ์ œํ’ˆ 96
      4. 11.6.4 ์ „๋žต 96
      5. 11.6.5 ์ฃผ์š” ๊ฐœ๋ฐœ 96
    7. 11.7 Teva Pharmaceutical Industries Ltd. 97
      1. 11.7.1 ํšŒ์‚ฌ ๊ฐœ์š” 97
      2. 11.7.2 ์žฌ๋ฌด 97
      3. 11.7.3 ์ œํ’ˆ 97
      4. 11.7.4 ์ „๋žต 97
      5. 11.7.5 ์ฃผ์š” ๊ฐœ๋ฐœ 97
    8. 11.8 Merck & Co. Inc 98
      1. 11.8.1 ํšŒ์‚ฌ ๊ฐœ์š” 98
      2. 11.8.2 ์žฌ๋ฌด 98
      3. 11.8.3 ์ œํ’ˆ 98
      4. 11.8.4 ์ „๋žต 98
      5. 11.8.5 ์ฃผ์š” ๊ฐœ๋ฐœ 98
    9. 11.9 Novartis AG 99
      1. 11.9.1 ํšŒ์‚ฌ ๊ฐœ์š” 99
      2. 11.9.2 ์žฌ๋ฌด 99
      3. 11.9.3 ์ œํ’ˆ 99
      4. 11.9.4 ์ „๋žต 99
      5. 11.9.5 ์ฃผ์š” ๊ฐœ๋ฐœ 99
    10. 11.10 Otsuka Holdings Co. Ltd 100
      1. 11.10.1 ํšŒ์‚ฌ ๊ฐœ์š” 100
      2. 11.10.2 ์žฌ๋ฌด 100
      3. 11.10.3 ์ œํ’ˆ 100
      4. 11.10.4 ์ŠคํŠธ๋ผtegy 100
      5. 11.10.5 ์ฃผ์š” ๊ฐœ๋ฐœ 100
    11. 11.11 Consern Pharma Private Limited 101
  12. 12 ๊ฒฐ๋ก 
    1. 12.1 ์ฃผ์š” ์กฐ์‚ฌ ๊ฒฐ๊ณผ 103
      1. 12.1.1 CEO์˜ ๊ด€์  103
      2. 12.1.2 ์ฃผ๋ชฉํ•ด์•ผ ํ•  ์ฃผ์š” ํšŒ์‚ฌ 103
      3. 12.1.3 ์‹์ƒํ™œ ์˜ˆ์ธก ๋งž์ถคํ˜• ์˜์–‘์‚ฐ์—… ์‹œ๋Œ€์˜ ๋ณด์ถฉ์ œ 103
  13. 13 ๋ถ€๋ก
    1. 13.1 ๋…ผ์˜ ์ฒญ์‚ฌ์ง„ 105
    2. 13.2 ์ „๋ฌธ๊ฐ€ ์˜๊ฒฌ: ์˜ฅ์‹œํ† ์‹  107
    3. 13.3 ์ฐธ๊ณ ๋ฌธํ—Œ 107
Case Study Cover Image
์‚ฌ๋ก€ ์—ฐ๊ตฌ

Aerospace & Defense

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization โœ“ โœ“ โœ“
Direct Access to Analyst โœ“ โœ“ โœ“
Deliverable Format โœ“ โœ“ โœ“
Platform Access โœ— โœ— โœ“
Discount on Next Purchase 10% 15% 15%
Printable Versions โœ— โœ— โœ“